Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) after high-dose chemo/radiotherapy is the best treatment option for several hematologic malignancies. 1 The administration of a donor leucocyte infusion (DLI) is a treatment option in patients with relapse after HSCT. 2 From clinical studies, it has been demonstrated that the effect of DLI varies between the different types of leukemia, and between patients with the same type of leukemia. [3] [4] [5] Persistant remissions can be obtained in 70-80% of DLI-treated patients with chronic myeloid leukemia (CML), and in only 30% of patients with multiple myeloma. For an as yet unknown reason, DLI is less effective in acute myeloid leukemia (AML) and barely or not effective in patients with ALL or CLL. Unfortunately, at present no reliable markers are available predicting whether DLI will be successful in the treatment of relapse after HSCT.
The allogeneic antileukemic activity of DLI and HSCT is mainly caused by donor-derived NK cells and cytotoxic T-cells, collectively called killer lymphocytes. The two major cytotoxic mechanisms used by killer lymphocytes to exert cytotoxicity appear to be exocytosis of granules containing perforin/ granzyme B and the expression of FAS ligand. 6 Ligation of FAS ligand, expressed on the killer cell surface, with FAS/CD95 present on target cells results in FAS trimerization. This activates signalling pathways through FAS-associated death domain protein, leading to activation of caspase-8, resulting in programmed cell death. 7 Perforin and granzyme B are present in cytoplasmic granules of NK cells and activated CTLs. Upon interaction with target cells, these vesicles migrate rapidly towards the cellular contact site. 8 Thereafter, the vesicles fuse with the outer membrane of the killer cells, thus releasing their contents in the intercellular space. 9, 10 Perforin contributes in two ways to the elimination of target cells. After binding to the membrane of target cells, monomeric perforine molecules incorporate, in the presence of calcium, into the plasma membrane of target cells. Upon aggregation into polyperforins, hollow tube-like structures (pores) are made through the membrane, directly causing necrosis via osmolysis. 11, 12 In addition, perforin inserted into the plasma membrane serves as a transport medium for granzymes, including granzyme B, which activates caspase-8 and -3, leading to programmed cell death. 13 Although the exact mechanism of perforin in granzyme B transport is still under investigation, from studies with knockout mice, it has become clear that perforin is required for entry of granzyme B into the cytosol. [14] [15] [16] Recently, resistance to perforin-mediated membrane damage has been found to occur also in leukemic cells from some patients with AML and not in ALL cells 17 (Uharek et al. Blood 2000; 96: 97 part 1; abstract). The purpose of this study is to assess in which types of leukemia perforin-binding resistance can be found, and to examine whether a relation exists between leukemia with perforin-binding resistance and relapse following DLI.
Patients and methods

Patients
Peripheral blood containing 480% malignant cells was collected from 29 patients with hematologic malignancies. The patient population consisted of 10 patients with CML, seven with AML, four with ALL, two with NHL, and six with CLL. Mononuclear cells were isolated via a Ficoll-Paque gradient (Amersham, Uppsala, Sweden), and cells were tested either directly or stored at À801C in RPMI (Gibco, Grand Island, NY, USA) containing 20% fetal calf serum (FCS) (Integro, Zaandam, Netherlands) and 10% DMSO (Merck, Darmstadt, Germany). FACS analysis was performed on either fresh or thawed samples using FSC, SSC, CD45, CD20, CD19, and CD7 as parameters to identify the leukemic/lymphoma cell population. During analysis of patients (with CML Ph þ PBMC 480%), malignant cells were positively selected by FACS. CML malignant cells were identified based on low CD45 expression and FSC/SSC parameters, whereas malignant cells from other types of leukemia could be readily identified by the mentioned parameters. Patients treated with transplant or DLI were usually at complete remission.
K562 and Jurkat cell cultures
The K562 erythroleukemic cell line and Jurkat T-cell line were obtained from ATCC (Rockville, MD, USA) and cultured in RPMI supplemented with 10% FCS, 20 nM glutamine, 100 IU/ml penicillin, and 100 mg/ml streptamycine (Invitrogen, Grand Island, NY, USA). Cells were routinely seeded in tissue culture flasks at a density of 0.5 Â 10 6 /ml and split 1:5 after 3 days in culture.
Reagents
Propidium iodide (PI; ICN, Aurora, OH, USA) was dissolved in PBS, resulting in 0.5 mg/ml PI stock solution. Anti-CD45, -CD20, -CD19, -CD7, IgG isotype controls, and anti-perforin monoclonal antibodies (clone dG9) were obtained from Becton Dickinson (San Jose, CA, USA), and anti-FAS (IgM anti-CD95) from Immunotech (Marseille, France). The occurrence of apoptosis was determined with a PI/Annexin-V kit, which included binding buffer for Annexin-V (Beckton Dickinson, San Diego, CA, USA).
Isolation and testing of NK-cell granules
PBMCs were isolated from buffy coats using a Ficoll-Paque gradient. Subsequently, NK cells were isolated via MACS. To this end, a ratio of 1 Â 10 7 PBMCs to 20 ml anti-CD56 MACS beads (Miltenyi Biotec, Bergisch-Gladbach, Germany) was incubated for 15 min at 61C using bi-directional rotation. After washing with PBS, the cells were centrifugated for 10 min at 300 g. The cells were resuspended in 10 ml PBS and NK cells were positively selected using an LS column. On average, 4.5 Â 10 7 NK cells (71.2 Â 10 7 ) could be isolated from 2.4 Â 10 9 leucocytes (74.7 Â 10 8 ) present in buffy coats (n ¼ 8). Lysates from NK cells were prepared as described previously. 17 In summary, a minimum of 1 Â 10 7 NK cells were resuspended in 200 ml PBS containing 1 mM EGTA and 1 mM MgCl 2 , and 3 Â snap frozen in isopropanol on dry ice, followed by thawing at room temperature. After centrifugation at 41C for 5 min at 12 000 g, the pellet was discarded and supernatant containing NK-cell granules was passed through a 0.22 mm filter (Costar, Corning, NY), aliquoted and stored at À801C before use. NK-cell granules were tested for its ability to lyse red blood cells and K562 cells, and protein concentration was determined using the micro-BCA assay (Pierce, Rockford, IL, USA). Only batches of perforin able to lyse 470% of K562 cells and 495% of RBC were used to analyse the perforin resistance of leukemic cells.
Detection of granule-and FAS-mediated cytotoxicity
In order to measure the sensitivity for perforin-mediated cytotoxicity, a volume of 25 ml of a 1 Â 10 6 cells/ml target cell suspension was incubated with 25 ml of NK lysates for 1 h at 371C. When patient samples were tested, K562 cells were included as positive control to assure the cytotoxic potential of NK-cell granules. Following incubation with granules, dead cells were stained with 10 ml of the PI solution for 15 min at room temperature, followed by addition of 200 ml PBS. Dead cells were identified by flow cytometry. In order to measure the sensitivity for IgM anti-FAS-mediated cytotoxicity, a volume of 1 ml of a 0.5 Â 10 6 cells/ml target cell suspension was incubated with 2 ml of a 1 mg/ml anti-FAS suspension for 4 h at 371C. When patient samples were tested, Jurkat T cells were included as positive control to assure the cytotoxic potential of anti-FAS. Following incubation, cells were washed, resuspended in binding buffer and 100 ml cells were stained in the dark with 10 ml PI and 5 ml annexin-V. After addition of 400 ml binding buffer, apoptotic or dead cells were identified by flow cytometry. The percentage of specific lysis caused by perforin of IgM anti-FAS was determined as described previously. 17 
Statistical analysis
The Mann-Whitney test and the Spearman rank correlation were used to compare the cytotoxicity caused by NK-cell granules containing perforin and anti-FAS.
Results
In control experiments, it was shown that cell death of K562 cells caused by NK-cell granules could be blocked by preincubating NK-cell granules with anti-perforin antibodies (Figure 1) . Lysis of human erythocytes by NK-cell granules could also be blocked by anti-perforin antibodies (Figure 2 ). Control IgG2b antibodies did not prevent lysis of K562 cells or erythrocytes. The results indicate that perforin is the essential constituent in the isolated granules responsible for pore formation.
We next examined whether resistance towards perforin pore formation and FAS aggregation could be found in leukemic cells from patients with different types of leukemia. To this end, we examined leukemic cells of 29 and 27 patients, respectively, for resistance against treatment with NK-cell granules containing perforin or IgM anti-FAS. The results indicate that treatment with NK-cell granules resulted in a significant higher percentage of PI-positive cells compared with anti-FAS resulting in PI-positive and/or annexin-V positivity (Po0.001, Mann-Whitney) ( Figure 3 ). As expected, no significant relation was found in paired samples (n ¼ 27) between the percentage of granuleinduced PI-positive cells and anti-FAS-induced PI-positive and/ or annexin-V positive cells (P ¼ ns, Spearman rank correlation). Sensitivity to anti-FAS, defined as a % above the mean plus standard deviation of values obtained from all 27 patients (c.q. 416%), was found in six patients (2 Â CML, 1 Â NHL, 1 Â B-ALL, 1 Â AML, and 1 Â B-CLL). No significant difference in sensitivity to anti-FAS could be found between different types of leukemia.
Leukemic/lymphoma cells from patients with AML, CML, B-CLL, B-ALL, and NHL were compared for their sensitivity towards granule-mediated lysis, together with K562 cells (Figure 4 ). Resistance towards perforin pore formation was defined as lysis less than the mean minus the standard deviation of all % specific lysis values obtained. By this criterion, perforinresistant cells were found exclusively in leukemic cells from patients with myeloid leukemia (in seven out of 10 CML and in three out of seven AML patients), whereas leukemic/lymphoma cells from all patients with lymphoid malignancies were sensitive. The results indicate that myeloid leukemic cells (CML plus AML) are more resistant than lymphoid/lymphoma leukemic cells (B-CLL plus B-ALL plus NHL; Po0.001, Mann Whitney), whereas B-CLL leukemic cells are more sensitive than all other types of leukemic cells tested (Po0.001). In order to analyze whether sensitivity of leukemic cells to perforin pore formation is related to the effect of HSCT with or without DLI, leukemic cells from 10 patients were studied, obtained at relapse after HSCT just prior to DLI ( Table 1 ). The results indicate that the effectiveness of treatment with DLI was not associated with sensitivity of leukemic cells to perforin pore formation ( Figure 5 ).
Discussion
Stimulated by the reported finding that leukemic cells from patients with AML can show resistance to perforin, 17 we studied perforin and also FAS-ligand resistance in lymphoid and myeloid types of leukemia. Perforin was clearly more efficient in killing leukemic cells compared with anti-FAS. In line with previous studies, perforin resistance could indeed be demonstrated in leukemic cells from some patients with AML. However, we found an even more pronounced resistance in leukemic cells from patients with CML.
Leukemic cells can use a variety of tumor escape mechanisms in order to prevent killer-cell-mediated elimination. Escape can be mediated by downregulation of HLA, secretion of suppressive cytokines or apoptosis-inducing ligands, and insensitivity to apoptosis-inducing ligands such as FAS ligand. 18, 19 The comparison made in this study between FAS-mediated apoptosis and perforin-mediated killing indicated that leukemic cells are more susceptible in vitro to elimination by perforin than by anti-FAS. The relative resistance of leukemic cells towards FASmediated apoptosis as found in this study is in line with data from previous reports also describing leukemia cell resistance to FAS ligation. Although we have not investigated the underlying mechanisms of resistance to FAS ligation, data from these previous reports show that leukemic cells can be insensitive to anti-FAS either by lacking expression of FAS/CD95, secretion of soluble FAS to block the FAS ligand, or low Bax/Bcl-2 ratios, thus preventing apoptosis. [20] [21] [22] In this study, we found that leukemic cells not only from patients with AML but also from CML were resistant to perforinmediated killing. This suggests that myeloid leukemic cells may show a higher degree of resistance towards perforin compared to lymphoid cells. It is unknown whether the 'normal' Figure 1 Inhibition of perforin-mediated K562 lysis by anti-perforin. K562 cells were incubated for 1 h at 371C with medium (a), 30 mg of NKcell lysate (b) or 30 mg of NK-cell lysate pretreated with anti-perforin (c). Thereafter, cells were incubated with PI to identify the dead cells as described in Patients and methods.
Figure 2
Inhibition of perforin-mediated erythrocyte lysis by antiperforin. Erythrocytes cells were incubated for 1 h at 371C with water to induce maximal lysis, buffer to measure background lysis, 30 mg of NK-cell lysate, or 30 mg of NK-cell lysate pretreated with different amounts (62.5 or 200 mg/ml) of anti-perforin. Thereafter, the supernatant was harvested and analyzed as described in Patients and methods.
Figure 3
Sensitivity of leukemic cells to perforin and anti-Fas. Leukemic/lymphoma cells were incubated for 1 h at 371C with medium, anti-FAS or 30 mg of NK-cell lysate. Thereafter, cells were incubated with PI and the percentage of specific lysis was determined by flow cytometry as described in Patients and methods. The solid lines represents the median values obtained.
counterparts in these patients also have a comparable resistance. It has been reported, however, that human polymorphonuclear leucocytes (PMNs) are more resistant to killing by murine perforin than lymphocytes and monocytes, 23 which is in line with the finding that perforin is constitutively expressed in PMNs. 24 The physiological relevance of this may relate to the co-presence of PMNs and killer cells at sites of inflammation. The occurrence and clinical significance of perforin resistance as a tumor-escape mechanism has scarcely been studied. This is mainly due to the fact that the integration of perforin into lipid bilayers is not fully understood, although it has been shown that perforin itself is essential for the delivery of granzyme B into the cytosol of target cells. [14] [15] [16] 25 Killer cells are known to be highly resistant to exogenously added NK-cell granules or purified perforin. 26, 27 However, the mechanism(s) employed by killer cells against granule-mediated fratricide is unknown, although some data have been published suggesting that surface proteins may be involved in this. 28, 29 The use of perforin resistance as a tumor-escape mechanism by leukemic cells could clarify the fact that DLI for the treatment of relapse does not always cause efficient eradication of leukemic cells. In the small number of patients tested, no relation could be found between perforin resistance of leukemic cells and the occurrence of relapse. This indicates that, as a single parameter, measurement of perforin resistance of leukemic cells has no predictive value in HLA-matched hematopoietic transplantation. It is nevertheless conceivable that this parameter may provide relevant additional information in combination with the expression (c.q. absence) of killer inhibitory ligands on leukemic cells, or in a HLA-mismatched setting in which NK cells can be activated by lack of KIR ligation. 30 Indeed, in recent studies it was shown that in patients transplanted with KIR incompatible stem-cell donors, NK-cell alloreactivity could prevent leukemic relapse and graft rejection 
Figure 5
Relation between sensitivity to perforin and the effect of DLI in CML. The sensitivity of leukemic/lymphoma cells to perforinmediated lysis was determined as described in the legend to Figure 3 . Filled and open circles represent values of specific lysis obtained after testing leukemic cells from patients who suffered from relapse or remained free from relapse after DLI, respectively.
Figure 4
Relative resistance of myeloid leukemia to perforin. The sensitivity of leukemic/lymphoma cells to perforin-mediated lysis was determined as described in the legend to Figure 3 and even protect patients against GVHD. 31, 32 Next to perforin resistance and KIR incompatibility, other parameters which may contribute to prediction of relapse include the number of NK cells infused during DLI, sensitivity of leukemic cells for other apoptosis-inducing molecules such as TRAIL, TNFalpha, and FAS ligand, HLA, and expression of adhesion molecules on leukemic cells.
